NCT07072793View on ClinicalTrials.gov

A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

CompletedOBSERVATIONAL
Enrollment

84,584

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
COVID-19 (Coronavirus Disease 2019)
Interventions
DRUG

nirmatrelvir-ritonavir

Participants with confirmed diagnosis of Covid-19 and with mild to moderate symptoms at high-risk for progressing to severe disease

Trial Locations (1)

10001

Pfizer New York, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07072793 - A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe | Biotech Hunter | Biotech Hunter